↓ Skip to main content

American Association for Cancer Research

Article Metrics

Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B1 Pharmacokinetics in Human Volunteers

Overview of attention for article published in Cancer Prevention Research, December 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
7 news outlets
policy
1 policy source
twitter
6 tweeters
facebook
2 Facebook pages
video
3 video uploaders

Citations

dimensions_citation
67 Dimensions

Readers on

mendeley
93 Mendeley
citeulike
1 CiteULike
Title
Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B1 Pharmacokinetics in Human Volunteers
Published in
Cancer Prevention Research, December 2009
DOI 10.1158/1940-6207.capr-09-0099
Pubmed ID
Authors

Carole Jubert, John Mata, Graham Bench, Roderick Dashwood, Cliff Pereira, William Tracewell, Kenneth Turteltaub, David Williams, George Bailey

Abstract

Chlorophyll (Chla) and chlorophyllin (CHL) were shown previously to reduce carcinogen bioavailability, biomarker damage, and tumorigenicity in trout and rats. These findings were partially extended to humans, where CHL reduced excretion of aflatoxin B(1) (AFB(1))-DNA repair products in Chinese unavoidably exposed to dietary AFB(1). However, neither AFB(1) pharmacokinetics nor Chla effects were examined. We conducted an unblinded crossover study to establish AFB(1) pharmacokinetic parameters among four human volunteers, and to explore possible effects of CHL or Chla cotreatment in three of those volunteers. For protocol 1, fasted subjects received an Institutional Review Board-approved dose of 14C-AFB(1) (30 ng, 5 nCi) by capsule with 100 mL water, followed by normal eating and drinking after 2 hours. Blood and cumulative urine samples were collected over 72 hours, and 14C- AFB(1) equivalents were determined by accelerator mass spectrometry. Protocols 2 and 3 were similar except capsules also contained 150 mg of purified Chla or CHL, respectively. Protocols were repeated thrice for each volunteer. The study revealed rapid human AFB(1) uptake (plasma k(a), 5.05 + or - 1.10 h(-1); T(max), 1.0 hour) and urinary elimination (95% complete by 24 hours) kinetics. Chla and CHL treatment each significantly impeded AFB(1) absorption and reduced Cmax and AUCs (plasma and urine) in one or more subjects. These initial results provide AFB(1) pharmacokinetic parameters previously unavailable for humans, and suggest that Chla or CHL co-consumption may limit the bioavailability of ingested aflatoxin in humans, as they do in animal models.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Kenya 1 1%
Australia 1 1%
Unknown 89 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 25%
Student > Master 18 19%
Student > Bachelor 14 15%
Student > Ph. D. Student 14 15%
Student > Doctoral Student 4 4%
Other 11 12%
Unknown 9 10%
Readers by discipline Count As %
Medicine and Dentistry 17 18%
Agricultural and Biological Sciences 16 17%
Chemistry 11 12%
Biochemistry, Genetics and Molecular Biology 8 9%
Environmental Science 7 8%
Other 21 23%
Unknown 13 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 71. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2021.
All research outputs
#382,709
of 18,414,344 outputs
Outputs from Cancer Prevention Research
#53
of 1,208 outputs
Outputs of similar age
#3,052
of 166,192 outputs
Outputs of similar age from Cancer Prevention Research
#1
of 29 outputs
Altmetric has tracked 18,414,344 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,208 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.